🚨 Investor Watchout:
- Regulatory delays in key markets (e.g., Canada, US) could impact timelines.
- Pricing pressure in generics, especially in the US, remains a structural risk.
- R&D expenses may rise before monetization of biosimilars and complex generics.
📌 Major Key Points:
- Strong pipeline in biosimilars and complex generics.
- Focus on GLP-1 (semaglutide) for diabetes/obesity—potential blockbuster.
- Expanding presence in emerging markets and India’s domestic formulation business.
🚀 Future Growth Planning:
- Targeting global obesity and diabetes markets via GLP-1 generics.
- Scaling up API exports and contract manufacturing.
- Strategic acquisitions in specialty and OTC segments.
🧭 Strategy Outlook:
- R&D-led growth with focus on high-margin complex molecules.
- Diversification across geographies to reduce US dependency.
- Digital transformation in supply chain and patient engagement.